-
India to Block $1.3 Billion Chinese Pharmaceutical Takeover, Sources Say
Tensions between India and China -- the South Asian nation’s biggest trading partner -- have escalated amid a renewed spat over territory in a remote area of the Himalayas, one of the most serious flareups since a border war in 1962.
- Categories
- Health Care
- Region
- South Asia
- Tags
- China, India, pharmaceutical industry, trade
-
Price fixation of essential drugs hits profitability: Novartis
The government's push for prescribing the drugs by generic names could pose further challenges, Novartis India said in the latest annual report for 2016-17.
- Categories
- Health Care
- Region
- South Asia
-
Q&A: Rajeev Venkayya on why vaccines are a worthy investment
Venkayya has seen vaccines from every angle. Before launching Takeda’s global vaccine business five years ago, he served as senior director for biodefense at the White House and director of global health delivery at the Bill & Melinda Gates Foundation. The success of vaccines going forward, he says, requires public and policy support for investments “to make sure that we're driving strong immunization coverage everywhere but also investing in new vaccines for the diseases that should be vaccine preventable,” he said.
- Categories
- Health Care
-
A Tale of Two Anti-Ebola Drugs
Thanks to the rapid and effective response coordinated by the World Health Organization (WHO) and its partners, the outbreak appears to have been brought under control. That’s a huge relief. But does that mean our toolbox is indeed adequately equipped to combat the virus? What if EVD, which kills 25 to 90 percent of those who become infected, again spread like wildfire? To address these questions, the story of China’s efforts to develop anti-Ebola drugs is illustrative of the opportunities and challenges we face in ensuring global health security.
- Categories
- Health Care
- Tags
- China, drugs, ebola, pharmaceutical industry, WHO
-
Press Release: American Cancer Society and Clinton Health Access Initiative Announce Collaborations with Pfizer and Cipla to Increase Access to Lifesaving Cancer Treatment in Africa
"For more than a hundred years, the American Cancer Society and our volunteers have led the fight for a world without cancer, and we're committed to making sure that the progress we've made in the United States is not limited to our borders," stated Gary M. Reedy, CEO of the American Cancer Society. "Every person with cancer deserves access to treatment, no matter where they live. Collaborating with companies like Pfizer and Cipla is a critical next step toward leveling the playing field for people with cancer and saving lives in this part of the world."
- Categories
- Health Care
-
WHO creates controversial ‘reserve’ list of antibiotics for superbug threats
Such resistance has created a world in which even the most minor of infections and illnesses can quickly turn deadly and in which diseases once thought conquered, such as tuberculosis and gonorrhea, are becoming untreatable in more and more cases.
- Categories
- Health Care
-
Amazon poised to disrupt pharmaceuticals
Amazon’s disruption in the retail and logistics space is unprecedented and in need of no introduction. However, in its typical style, while everyone has been focusing on what we perceive to be its core business, it has quietly been thinking of swallowing a completely different industry – in this case, pharmaceuticals.
- Categories
- Health Care
-
Large market share for non-quality-assured malaria medicines in Africa
A new study of malaria medicine quality in 8 sub-Saharan African countries has found a large and potentially growing market for non-quality-assured (QA) malaria treatments—medicines not pre-approved by global health organizations - as much as 20% of the private-sector market in Kenya, and 42% in the Democratic Republic of Congo (DRC).
- Categories
- Health Care
- Region
- Sub-Saharan Africa
- Tags
- Africa, drugs, health care, malaria, medicines, pharmaceutical industry, WHO
Parent Organization
